- Companies
- Hester Biosciences
Hester Biosciences Valuation Multiples
Hester Biosciences is valued at $213M as of November 2026, a 6.2x revenue multiple. In the last fiscal year, Hester Biosciences revenue was $36M and Hester Biosciences EBITDA was $11M.
Hester Biosciences Overview
About Hester Biosciences
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
Founded
1987
HQ
Employees
562
Website
Financials (Last FY)
EV
$220M
Valuation Multiples
Start free trialHester Biosciences Financials
Hester Biosciences reported last fiscal year revenue of $36M and EBITDA of $11M.
In the same fiscal year, Hester Biosciences generated $26M in gross profit, $11M in EBITDA, and $6M in net income.
Hester Biosciences P&L
In the most recent fiscal year, Hester Biosciences reported revenue of $36M and EBITDA of $11M.
Hester Biosciences is profitable as of last fiscal year, with gross margin of 72%, EBITDA margin of 30%, and net margin of 17%.
Financial data powered by Morningstar, Inc.
Hester Biosciences Stock Performance
Hester Biosciences has current market cap of $213M, and enterprise value of $220M.
Market Cap Evolution
Hester Biosciences' stock price is $25.00.
Hester Biosciences has an EPS (earnings per share) of $0.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $220M | $213M | 0.5% | - | - | - | $0.70 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHester Biosciences Valuation Multiples
Hester Biosciences trades at 6.2x EV/Revenue multiple, and 20.4x EV/EBITDA.
Hester Biosciences Financial Valuation Multiples
As of November 19, 2026, Hester Biosciences has market cap of $213M and EV of $220M.
Hester Biosciences has a P/E ratio of 35.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hester Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Hester Biosciences Margins & Growth Rates
In the most recent fiscal year, Hester Biosciences reported gross margin of 72%, EBITDA margin of 30%, and net margin of 17%.
Hester Biosciences Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
Hester Biosciences Operational KPIs
Hester Biosciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Hester Biosciences Competitors
Hester Biosciences competitors include Racura Oncology, Lineage Cell Therapeutics, Newron Pharmaceuticals, Tanvex BioPharma, AC Immune, Oryzon Genomics, Celon Pharma, Yarrow Bioscience, Transgene and Bicycle Therapeutics.
Most Hester Biosciences public comparables operate across Biopharmaceuticals, Life Sciences Tools and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2M | ($8M) | 94.0x | 94.0x | (24.6x) | (55.1x) | |||
| $15M | ($70M) | 11.5x | 17.9x | (2.4x) | (5.2x) | |||
| $21M | ($9M) | 10.4x | 19.0x | (23.9x) | (6.8x) | |||
| $12M | ($34M) | 21.5x | 20.7x | (7.6x) | - | |||
| $4M | ($83M) | 29.4x | 5.1x | (1.5x) | - | |||
| - | ($6M) | - | 30.8x | (32.5x) | (23.4x) | |||
| $48M | $4M | 4.9x | 3.5x | 57.6x | 28.6x | |||
| - | - | - | - | - | - | |||
This data is available for Pro users. Sign up to see all Hester Biosciences competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by Hester Biosciences
Hester Biosciences has acquired 1 company to date.
Last acquisition by Hester Biosciences was on November 21st 2014. Hester Biosciences acquired Gujarat Agrofarm Ltd. for $84K (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Hester Biosciences
| Description | Gujarat Agrofarm Ltd. is an Ahmedabad-based manufacturer in Gujarat, India. It produces microbial growth media, tissue culture nutrients, and agar-based substrates for agriculture and biotechnology labs. The company supplies ready-to-use plates and powdered formulations for plant propagation, mushroom cultivation, and bacterial culturing. Its products support sericulture, horticulture, and research institutes across western India. |
| HQ Country | |
| HQ City | Ahmedabad |
| Deal Date | 21 Nov 2014 |
| Valuation | $84K |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Hester Biosciences acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hester Biosciences
| When was Hester Biosciences founded? | Hester Biosciences was founded in 1987. |
| Where is Hester Biosciences headquartered? | Hester Biosciences is headquartered in India. |
| How many employees does Hester Biosciences have? | As of today, Hester Biosciences has over 562 employees. |
| Is Hester Biosciences publicly listed? | Yes, Hester Biosciences is a public company listed on Bombay Stock Exchange. |
| What is the stock symbol of Hester Biosciences? | Hester Biosciences trades under 524669 ticker. |
| When did Hester Biosciences go public? | Hester Biosciences went public in 2015. |
| Who are competitors of Hester Biosciences? | Hester Biosciences main competitors include Racura Oncology, Lineage Cell Therapeutics, Newron Pharmaceuticals, Tanvex BioPharma, AC Immune, Oryzon Genomics, Celon Pharma, Yarrow Bioscience, Transgene, Bicycle Therapeutics. |
| What is the current market cap of Hester Biosciences? | Hester Biosciences' current market cap is $213M. |
| What is the current revenue of Hester Biosciences? | Hester Biosciences' last fiscal year revenue is $36M. |
| What is the current EV/Revenue multiple of Hester Biosciences? | Current revenue multiple of Hester Biosciences is 6.2x. |
| Is Hester Biosciences profitable? | No, Hester Biosciences is not profitable. |
| How many companies Hester Biosciences has acquired to date? | As of November 2026, Hester Biosciences has acquired 1 company. |
| What was the largest acquisition by Hester Biosciences? | $84K acquisition of Gujarat Agrofarm Ltd. on 21st November 2014 was the largest M&A Hester Biosciences has done to date. |
| What companies Hester Biosciences acquired? | Hester Biosciences acquired Gujarat Agrofarm Ltd.. |
| In how many companies Hester Biosciences has invested to date? | Hester Biosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Hester Biosciences
Lists including Hester Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




